{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:19:08Z","timestamp":1786994348658,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T00:00:00Z","timestamp":1521158400000},"content-version":"vor","delay-in-days":408,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Metabolism"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.molmet.2016.12.009","type":"journal-article","created":{"date-parts":[[2017,1,2]],"date-time":"2017-01-02T14:33:04Z","timestamp":1483367584000},"page":"226-231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects"],"prefix":"10.1016","volume":"6","author":[{"given":"Tsuyoshi","family":"Yanagimachi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Honjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemitsu","family":"Sakagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroya","family":"Kitsunai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Takiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5083-2620","authenticated-orcid":false,"given":"Atsuko","family":"Abiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Kieffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Haneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmet.2016.12.009_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.pharmthera.2012.05.009","article-title":"Targeting the glucagon receptor family for diabetes and obesity therapy","volume":"135","author":"Cho","year":"2012","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.molmet.2016.12.009_bib2","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1053\/j.gastro.2010.01.049","article-title":"Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet \u03b1-cells and promotes insulin secretion","volume":"138","author":"Fujita","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmet.2016.12.009_bib3","doi-asserted-by":"crossref","first-page":"G608","DOI":"10.1152\/ajpgi.00024.2010","article-title":"Differential processing of pro-glucose-dependent insulinotropic polypeptide in gut","volume":"298","author":"Fujita","year":"2010","journal-title":"The American Journal of Physiology Gastrointestinal and Liver Physiology"},{"issue":"Suppl 1","key":"10.1016\/j.molmet.2016.12.009_bib4","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/jdi.12490","article-title":"Incretin-based drugs for type 2 diabetes: focus on East Asian perspectives","volume":"7","author":"Seino","year":"2016","journal-title":"Journal of Diabetes Investigation"},{"key":"10.1016\/j.molmet.2016.12.009_bib5","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00125-015-3842-y","article-title":"Pancreatic glucose-dependent insulinotropic polypeptide (GIP) (1-30) expression is upregulated in diabetes and PEGylated GIP(1-30) can suppress the progression of low-dose-STZ-induced hyperglycaemia in mice","volume":"59","author":"Yanagimachi","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2016.12.009_bib6","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1210\/endo.137.11.8895386","article-title":"Distribution of glucagon receptors on hormone-specific endocrine cells of rat pancreatic islets","volume":"137","author":"Kieffer","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.molmet.2016.12.009_bib7","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00125-014-3283-z","article-title":"Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?","volume":"57","author":"Wewer Albrechtsen","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2016.12.009_bib8","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1530\/EJE-13-0941","article-title":"Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans","volume":"170","author":"Bak","year":"2014","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.molmet.2016.12.009_bib9","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/jdi.12400","article-title":"Postabsorptive hyperglucagonemia in patients with type 2 diabetes mellitus analyzed with a novel enzyme-linked immunosorbent assay","volume":"7","author":"Matsuo","year":"2015","journal-title":"Journal of Diabetes Investigation"},{"key":"10.1016\/j.molmet.2016.12.009_bib10","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/dom.12352","article-title":"Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies. Diabetes","volume":"11","author":"Bak","year":"2014","journal-title":"Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2016.12.009_bib11","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1210\/er.2014-1035","article-title":"Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors","volume":"35","author":"Mulvihill","year":"2014","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.molmet.2016.12.009_bib12","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1007\/s00125-014-3299-4","article-title":"Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes","volume":"57","author":"Omar","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2016.12.009_bib13","article-title":"Cellular sites and mechanisms linking reduction of dipeptidyl peptidase-4 activity to control of incretin hormone action and glucose homeostasis","author":"Mulvihill","year":"2016","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.molmet.2016.12.009_bib14","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1210\/endo.136.8.7628397","article-title":"Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in\u00a0vitro and in\u00a0vivo by dipeptidyl peptidase IV","volume":"136","author":"Kieffer","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.molmet.2016.12.009_bib15","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.2337\/db16-0107","article-title":"Quantification of the contribution of GLP-1 to mediating insulinotropic effects of DPP-4 inhibition with vildagliptin in healthy subjects and patients with type 2 diabetes using exendin [9-39] as a GLP-1 receptor antagonist","volume":"65","author":"Nauck","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2016.12.009_bib16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF02738808","article-title":"Truncated and full-length glucagon-like peptide-1 (GLP-1) differentially stimulate intestinal somatostatin release","volume":"1","author":"Brubaker","year":"1997","journal-title":"Endocrine"},{"key":"10.1016\/j.molmet.2016.12.009_bib17","doi-asserted-by":"crossref","first-page":"E1010","DOI":"10.1152\/ajpendo.2000.278.6.E1010","article-title":"Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum","volume":"278","author":"Hansen","year":"2000","journal-title":"American Journal of Physiology Endocrinology and Metabolism"},{"key":"10.1016\/j.molmet.2016.12.009_bib18","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.2337\/db08-0958","article-title":"Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes","volume":"58","author":"Chia","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2016.12.009_bib19","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.2337\/db11-0979","article-title":"Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans","volume":"60","author":"Christensen","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2016.12.009_bib20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0167-0115(00)00170-1","article-title":"Metabolism of glucagon by dipeptidyl peptidase IV (CD26)","volume":"93","author":"Pospisilik","year":"2001","journal-title":"Regulatory Peptides"},{"key":"10.1016\/j.molmet.2016.12.009_bib21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.molmet.2016.12.009_bib22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0167-0115(94)90136-8","article-title":"The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects","volume":"51","author":"Elahi","year":"1994","journal-title":"Regulatory Peptides"},{"key":"10.1016\/j.molmet.2016.12.009_bib23","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00125-002-0878-6","article-title":"Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients","volume":"45","author":"Vilsb\u00f8ll","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2016.12.009_bib24","article-title":"Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: a randomized controlled trial in patients with type 2 diabetes","author":"Nauck","year":"2016","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2016.12.009_bib25","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2337\/db13-1455","article-title":"Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade","volume":"63","author":"Aulinger","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2016.12.009_bib26","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2337\/diabetes.53.5.1326","article-title":"Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors","volume":"53","author":"Hansotia","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2016.12.009_bib27","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.2337\/db07-0697","article-title":"Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice","volume":"56","author":"Flock","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2016.12.009_bib28","doi-asserted-by":"crossref","first-page":"209ra151","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans","volume":"5","author":"Finan","year":"2013","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.molmet.2016.12.009_bib29","doi-asserted-by":"crossref","first-page":"e9590","DOI":"10.1371\/journal.pone.0009590","article-title":"A\u00a0GIP receptor agonist exhibits beta-cell anti-apoptotic actions in rat models of diabetes resulting in improved beta-cell function and glycemic control","volume":"5","author":"Widenmaier","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.molmet.2016.12.009_bib30","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.2337\/dc13-0465","article-title":"Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies","volume":"36","author":"Calanna","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2016.12.009_bib31","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-013-2841-0","article-title":"Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies","volume":"56","author":"Calanna","year":"2013","journal-title":"Diabetologia"}],"container-title":["Molecular Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877816303167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877816303167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T04:18:53Z","timestamp":1539749933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212877816303167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S2212877816303167"],"URL":"https:\/\/doi.org\/10.1016\/j.molmet.2016.12.009","relation":{},"ISSN":["2212-8778"],"issn-type":[{"value":"2212-8778","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects","name":"articletitle","label":"Article Title"},{"value":"Molecular Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmet.2016.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The Authors. Published by Elsevier GmbH","name":"copyright","label":"Copyright"}]}}